Etiological treatment of chronic Chagas disease: Neglected 'evidence' by evidence-based medicine

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 4, 2007, Pages 717-726

  Viotti, Rodolfo ^a   Vigliano, Carlos ^b  

^a Hospital Eva Peron   (Argentina)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Chagas disease; Diagnosis; Etiological treatment; Pathogenesis; Pathology; Prognosis

Indexed keywords

ALLOPURINOL; ANTIPARASITIC AGENT; BENZNIDAZOLE; KINETOPLAST DNA; NIFURTIMOX;

AGAR GEL ELECTROPHORESIS; B LYMPHOCYTE; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; EOSINOPHIL; EPITHELIOID CELL; EVIDENCE BASED MEDICINE; EXERCISE TEST; FOLLOW UP; GENE AMPLIFICATION; HEART LEFT VENTRICLE ANEURYSM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE CONDUCTION; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAST CELL; NONHUMAN; PARASITE PREVALENCE; PARASITEMIA; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT;

CHAGAS DISEASE; CHRONIC DISEASE; ELECTROCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS;

EID: 34547905013     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.4.717     Document Type: Review

References (91)

1. Sackett DH, Busemberg WMC, Gray JAM, Haynes RB, Richardsen WS. Evidence based medicine: what it is and what it isn't. Br. Med. J. 312, 71-72 (1996).
2. Ham C, Hunter C, Robinson R. Evidence based policymaking. Br. Med. J. 310, 71-72 (1995).
3. Doval H, Tajer C. Introducción ¿Porqué un libro de cardiología basada en la evidencia. In: Evidencias en Cardiología III "De los ensayos clínicos a las conductas terapéuticas". GEDIC (Ed.). Buenos Aires, Argentina 35-44 (2003).
4. Moher D, Schulz K, Altman D; for the Consort Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 357, 1191-1195 (2001).
5. Samaja J. El producto del proceso de investigación. In: Epistemología y Metodología, Parte II. Eudeba (Ed.). Buenos Aires, Argentina 51-142 (1993).
6. Victora C, Jabicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. Am. J. Public Health 94 400-405 (2004).
7. Des Jarlais D, Lyles C, Crepaz N; and the TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am. J. Public Health 94, 361-366 (2004).
8. Ernst E, Canter PH. Limitations of "pragmatic" trials. Postgrad. Med. J. 181, 203 (2005).
9. Feldman AM, MacNamara D. Myocarditis. N. Engl. J. Med. 343, 1388-1398 (2000).
10. Organización Panamericana de la Salud. Estimación cuantitativa de la enfermedad de Chagas en las Américas, Montevideo, Uruguay: OPS/HDM/CD/425 (2006).
11. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 115, 1109-1123 (2007).
12. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a T. cruzi DNA sequence of inflammatory lesions in human chagasic cardiomyopathy. Am. J. Trop. Med. Hyg. 48, 348-357 (1993).
13. Higuchi M, De Brito T, Reis M et al. Correlation between T. cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc. Pathol. 2, 101-116 (1993).
14. Schijman AG, Vigliano CA, Viotti RJ et al. T. cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart disease. Am. J. Trop. Med. Hyg. 70, 210-220 (2004).
15. Ouaissi A, Da Silva A, Guevara A, Borges M, Guilvard E. T. cruzi-induced host immune system dysfunction: a rationale for parasite immunosuppressive factor(s) encoding gene targeting. J. Biomed. Biotechnol. 1, 111-117 (2001).
16. Andrade ZA. Immunopathology of Chagas disease. Mem. Inst. Oswaldo Cruz 94, 71-80 (1999).
17. Avila H, Pereira J, Thiemann O et al. Detection of T. cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J. Clin. Microbiol. 31, 2421-2426 (1993).
18. Salomone OA, Basquiera AL, Sembaj A et al. T. cruzi in persons without serologic evidence of disease, Argentina. Emerg. Infect. Dis. 9, 1558-1562 (2003).
19. Abbas A, Lichtman A, Pober J. Immunity to parasites. Evasion of immune mechanisms by parasites. In: Cellular and Mollecular Immunology, Fourth Edition. W.B. Saunders Company, PA, USA 357-360 (2000).
20. Elias F, Vigliano C, Laguens R, Levin MJ, Berek C. Analysis of the presence of T. cruzi in the heart tissue of three patients with chronic Chagas' heart disease. Am. J. Trop. Med. Hyg. 68, 242-247 (2003).
21. Koberle F. Cardiopatía chagásica. O Hospital 53, 311-346 (1958).
22. Mott KE, Hagstrom JWC. The pathologic lesions of the cardiac autonomic nervous system in chronic Chagas myocarditis. Circulation 31, 273-286 (1965).
23. Spotnitz MD, Lesch M. Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog. Cardiovasc. Dis. 49, 42-57 (2006).
24. Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39, 41-54 (2006).
25. Esteva M, Ruiz A, Cabeza Meckerr PM, Cazzulo J, Segura E, Laguens RP. Antigens of the microsomal fraction of T. cruzi produce pathology in mice. J. Protozool. 30, 1-14 (1983).
26. Lopez Bergami P, Cabeza Meckert PM, Kaplan D et al. Immunization with recombinant T. cruzi ribosomal P2β protein induces changes in the electrocardiogram of immunized mice. FEMS Immunol. Med. Microbiol. 18, 75-85 (1997).
27. Laguens RP, Cabeza Meckert PM, Chambo JG, Gelpi R. Chronic Chagas disease in the mouse II. Transfer of the heart disease by means of immunocompetent cells. Medicina 41, 40-43 (1981).
28. + T cells able to mediate parasite-specific delayed-type hypersensitivity play a role in the pathology of experimental Chagas' disease. Eur. J. Immunol. 17, 1027-1033 (1987).
29. Cabeza Meckert PM, Chambó JG, Laguens RP. Presence of cells producing antiheart autoantibodies in the inflammatory infiltrate of chronic chagasic myocarditis. Clin. Immunol. Immunopathol. 60, 137-144 (1991).
30. Laguens RP, Argel MI, Chambo J, Storino R, Cabeza Meckert PM. Presence of antiheart and antiskeletal muscle glycolipid autoantibodies in the sera of patients with chagasic cardiopathy. Can. J. Cardiol. 10, 769-776 (1994).
31. Levitus G, Hontebeyrie-Joskowicz M, Vanregenmortel M, Levin MJ. Humoral autoimmune response to ribosomal P-proteins in chronic Chagas heart disease. Clin. Exp. Immunol. 85, 413-417 (1991).
32. Cunha-Nero E, Duranti M, Gruber A et al. Autoimmunity in Chagas' disease cardiopathy: biological relevance of a cardiac myosin-specific epitope cross-reactive to an immunodominant T. cruzi antigen. Proc. Natl Acad. Sci. USA 92, 3541-3545 (1995).
33. Brener Z. Recent advances in the chemotherapy of Chagas disease. Mem. Inst. Oswaldo Cruz 79, 149-155 (1984).
34. Morris SA, Tanowitz HB, Wittner M, Bilezikian JP. Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 82, 1900-1909 (1990).
35. Rossi WA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am. Heart J. 120, 233-236 (1990).
36. Brandariz S, Schijman A, Vigliano C et al. Detection of parasite DNA in Chagas' heart disease. Lancet 346, 1370-1371 (1995).
37. Vago AR, Macedo AM, Adad SJ, Reis DD, Correa-Oliveira R. PCR detection of T. cruzi DNA in esophageal tissues of patients with chronic digestive Chagas' disease. Lancet 348, 891-892 (1996).
38. Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol. 21, 513-516 (2005).
39. Macedo AM, Machado CR, Oliveira RP, Pena SD. T. cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem. Inst. Oswaldo Cruz 99, 1-12 (2004).
40. Higuchi ML, Benvenuto LA, Reis MM, Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc. Res. 60, 96-107 (2003).
41. Tarleton R. Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. 31, 550-554 (2001).
42. Laguens R, Cabeza Meckert P, Vigliano C. Patogenia de la Miocarditis Chagásica Crónica Humana. Medicina 59, 63-68 (1999).
43. + T cells in T. cruzi infection. Immunol. Rev. 201, 304-317 (2004).
44. Bellotti G, Bocchi EA, de Moraes AV et al. In vivo detection of T. cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am. Heart J. 131, 301-307 (1996).
45. Añez N, Carrasco H, Parada H et al. Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg. 60, 726-732 (1999).
46. Basquiera AL, Sembaj A, Aguerri AM et al. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitemia detected by polymerase chain reaction. Heart 89, 1186-1190 (2003).
47. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J. Infect. Dis. 180, 480-486 (1999).
48. Elizari M. La Miocardiopatía Chagásica. Perspectiva histórica. Medicina 59, 25-40 (1999).
49. Laranja F, Dias E, Nobrega G, Miranda A. Chagas disease. A clinical, epidemiologic and pathologic study. Circulation 14, 1035-1060 (1956).
50. Puigbó J, Giordano H, Suárez C, Acquatella H, Combellas I. Aspectos clinicos en la enfermedad de Chagas. In: Actualizaciones en la Enfermedad de Chagas. Simposio Satélite. Madoery R, Madoery C y Cámera M (Ed.). Organismo oficial del Congreso Nacional de Medicina 27-38 (1993).
51. Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem. Inst. Oswaldo Cruz 94, 317-320 (1999).
52. Maguire J, Hoff R, Sherlock I et al. Cardiac morbidity and mortality due to Chagas disease: prospective electrocardiographic study of a Brazilian community. Circulation 75, 1140-1145 (1987).
53. Barret PA, Peter CT, Swan HJ, Singh BN, Mandel WJ. The fiequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog. Cardiovasc. Dis. 23, 299-319 (1981).
54. Carrasco H, Barboza J, Inglessis G, Fuenmayor A, Molina C. Left ventricular cineangiography in Chagas disease: detection of early myocardial damage. Am. Heart. J. 104, 595-602 (1982).
55. Acquatella H, Schiller N, Puigbo J et al. M-mode and two dimensional echocardiography in chronic Chagas heart disease: a clinical and pathological study. Circulation 62, 787-799 (1980).
56. Viotti R, Vigliano C, Laucella S et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90, 655-660 (2004).
57. Storino R. Estudios cardiológicos no invasivos. In: Enfermedad de Chagas. Storino R, Milei J, Mosby (Eds). Buenos Aires, Argentina 392-397 (1994).
58. de Paola A, Gomez J, Terzian A, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br. Heart J. 74, 293-295 (1995).
59. Viotti R, Vigliano C, Lococo B et al. Exercise stress testing as a predictor of progression of early chronic Chagas heart disease. Heart 92, 403-404 (2006).
60. Rodriguez-Salas L, Klein E, Acquatella H et al. Echocardiographic and clinical predictors of mortality in chronic Chagas disease. Echocardiography 15, 271-278 (1998).
61. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 115, 1101-1108 (2007).
62. Viotti R, Vigliano C, Lococo B et al. Clinical predictors of chronic chagasic myocarditis progression. Rev. Esp. Cardiol. 58, 1037-1044 (2005).
63. Viotti R, Vigliano C, Lococo B et al. Longterm cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann. Intern. Med. 144, 724-734 (2006).
64. Cançado JR. Tratamento específico. In: Cardiopatía Chagásica. Cançado JR, Chusrer M (Eds). Fundaçao Carlos Chagas, Belo Horizonte, Brazil 327-355 (1985).
65. Cançado JR. Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz 94, 331-335 (1999).
66. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole clinical and serologic evolution of patients with long-term follow-up. Am. Heart J. 127, 151-162 (1994).
67. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA. Reversibility of cardiac fibrosis in mice chronically infected with T. cruzi, under specific chemotherapy. Mem. Inst. Oswaldo Cruz 86, 187-200 (1991).
68. Garcia S, Ramos C, Senra J et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob. Agents Chemother. 49, 1521-1528 (2005).
69. Bustamante JM, Presti MS, Rivarola HW et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int. J. Antimicrob. Agents 29, 733-737 (2007).
70. Hyland KV, Leon JS, Daniels MD et al. Modulation of autoimmunity by treatment of an infectious disease. Infect. Immun. 75(7), 3641-3650 (2007).
71. Fabbro De Suasnabar D, Arias E, Streiger M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev. Inst. Med. Trop. Sao Paulo 42, 99-109 (2000).
72. Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev. Fac. Cien. Med. Univ. Nac. Cordoba 57, 135-162 (2000).
73. Viotti R, Vigliano C, Lococo B, Armenti H, Lapuente A, Segura E. Chronic chagasic cardiomyopathy: clinical and serologic evolution with and without benznidazole in long-term follow-up. In: XIII World Congress of Cardiology. Free Papers. Monduzzi (Ed.) 697-701 (1998).
74. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44, 29-37 (2002).
75. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 59, 526-529 (1998).
76. de Andrade AL, Zicker F, de Oliveira RM et al. Randomized trial of efficacy of benznidazole in treatment of early T. cruzi infection. Lancet 348, 1407-1413 (1996).
77. Francolino S, Fernandez Antunes A, Talice R et al. New evidence of spontaneous cure in human Chagas disease. Rev. Soc. Bras. Med. Trop. 36, 103-107 (2003).
78. Carbalho V, Sousa E, Vita J et al. Heart transplantation in Chagas disease, 10 years after initial experience. Circulation 94, 1815-1817 (1996).
79. Schijman A, Vigliano C, Burgos J et al. Early diagnosis of recurrence of T. cruzi infection by polymerase chain reaction after heart transplantation of a chronic Chagas heart disease patient. Heart Lung Transplant. 19, 1114-1117 (2000).
80. Diez M, Favaloro L, Bertolotti A et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am. J. Transplant. 7, 1633-1640 (2007).
81. Rivera J, Hillis LD, Levine BD. Reactivation of cardiac Chagas disease in acquired immunodeficiency syndrome. Am. J. Cardiol. 94, 1102-1103 (2004).
82. Sartori AM, Ibrahim KY, Nunes Westphalen EV et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann. Trop. Med. Parasitol. 101, 31-50 (2007).
83. Lambert N, Mehta B, Walters R, Eron JJ. Chagasic encephalitis as the initial manifestation of AIDS. Ann. Intern. Med. 144, 941-943 (2006).
84. Gurtler RE, Segura EL, Cohen JE. Congenital transmission of T. cruzi infection in Argentina. Emerg. Infect. Dis. 9, 29-32 (2003).
85. Hermann E, Truyens C, Alonso-Vega C et al. Congenital transmission of T. cruzi is associated with maternal enhanced parasitemia and decreased production of interferon-γ in response to parasite antigens. J. Infect. Dis. 189, 1274-1281 (2004).
86. Moraes-Souza H. Chagas infection transmission control: situation of transfusional transmission in Brazil and other countries of Latin America. Mem. Inst. Oswaldo Cruz 94, 419-423 (1999).
87. Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, Van der Stuyft P. The validity of serologic tests for T. cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 45, 554-561 (2005).
88. WHO Technical Report Series 905. Control of Chagas disease, Etiological treatment. Geneva, Switzerland (2002).
89. Jenicek M. Evidence-based medicine: fifteen years later. Golem the good, the bad, the ugly in need of a review? Med. Sci. Monit. 12, 241-251 (2006).
90. Urbina J, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19, 495-501 (2003).
91. Ferraz M, Gazzinelli R, Alves R, Urbina J, Romanha A. The anti- Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas disease is less dependent on γ interferon than that of Benznidazole. Antimicrob. Agents Chemother. 51, 1359-1364 (2007).